Coreâ binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (Iâ CBFit)
Ustun, Celalettin; Morgan, Elizabeth; Moodie, Erica E. M.; Pullarkat, Sheeja; Yeung, Cecilia; Broesby‐olsen, Sigurd; Ohgami, Robert; Kim, Young; Sperr, Wolfgang; Vestergaard, Hanne; Chen, Dong; Kluin, Philip M.; Dolan, Michelle; Mrózek, Krzysztof; Czuchlewski, David; Horny, Hans‐peter; George, Tracy I.; Kristensen, Thomas Kielsgaard; Ku, Nam K.; Yi, Cecilia Arana; Møller, Michael Boe; Marcucci, Guido; Baughn, Linda; Schiefer, Ana‐iris; Hilberink, J. R.; Pullarkat, Vinod; Shanley, Ryan; Kohlschmidt, Jessica; Coulombe, Janie; Salhotra, Amandeep; Soma, Lori; Cho, Christina; Linden, Michael A.; Akin, Cem; Gotlib, Jason; Hoermann, Gregor; Hornick, Jason; Nakamura, Ryo; Deeg, Joachim; Bloomfield, Clara D.; Weisdorf, Daniel; Litzow, Mark R.; Valent, Peter; Huls, Gerwin; Perales, Miguel‐angel; Borthakur, Gautam
2018-09
Citation
Ustun, Celalettin; Morgan, Elizabeth; Moodie, Erica E. M.; Pullarkat, Sheeja; Yeung, Cecilia; Broesby‐olsen, Sigurd ; Ohgami, Robert; Kim, Young; Sperr, Wolfgang; Vestergaard, Hanne; Chen, Dong; Kluin, Philip M.; Dolan, Michelle; Mrózek, Krzysztof ; Czuchlewski, David; Horny, Hans‐peter ; George, Tracy I.; Kristensen, Thomas Kielsgaard; Ku, Nam K.; Yi, Cecilia Arana; Møller, Michael Boe ; Marcucci, Guido; Baughn, Linda; Schiefer, Ana‐iris ; Hilberink, J. R.; Pullarkat, Vinod; Shanley, Ryan; Kohlschmidt, Jessica; Coulombe, Janie; Salhotra, Amandeep; Soma, Lori; Cho, Christina; Linden, Michael A.; Akin, Cem; Gotlib, Jason; Hoermann, Gregor; Hornick, Jason; Nakamura, Ryo; Deeg, Joachim; Bloomfield, Clara D.; Weisdorf, Daniel; Litzow, Mark R.; Valent, Peter; Huls, Gerwin; Perales, Miguel‐angel ; Borthakur, Gautam (2018). "Coreâ binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (Iâ CBFit)." Cancer Medicine 7(9): 4447-4455.
Abstract
BackgroundAlthough the prognosis of coreâ binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse.MethodsEleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22).ResultsComplete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median diseaseâ free (DFS) and overall (OS) survival were 20.8 and 31.2Â months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyperâ or hypodiploidy were included in a scoring system (named Iâ CBFit). DFS rate at 2Â years was 76% for patients with a lowâ risk Iâ CBFit score compared with 36% for those with a highâ risk Iâ CBFit score (PÂ <Â 0.0001). Lowâ vs highâ risk OS at 2Â years was 89% vs 51% (PÂ <Â 0.0001).ConclusionsIâ CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a lowâ risk Iâ CBFit score).CBF AML is relatively favorable AML; however, 30%â 40% of patients still relapse. There is no widely used scoring system to identify highâ risk patients. We here developed a novel scoring system (Iâ CBFit) can differ patients with high risk of treatment failure from this with a lower risk score. This scoring system can be very useful to prognosticate and thus to choose right therapy (eg, personalize therapy) in CR1.Publisher
Wiley Periodicals, Inc.
ISSN
2045-7634 2045-7634
Other DOIs
Types
Article
Metadata
Show full item recordCollections
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.